Paper Details

  1. Home
  2. Paper Details

Vigabatrin for refractory partial epilepsy.

Author: HemmingKarla, HuttonJane L, MaguireMelissa J, MarsonAnthony G

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Vigabatrin is an antiepileptic drug that is used for the treatment of refractory epilepsy. Although vigabatrin is generally well tolerated, it can cause asymptomatic visual field constriction.
Paper Details　
Original Abstract of the Article :
Epilepsy is a common neurological condition which affects between 0.5% and 1% of the population. Approximately 30% of people with epilepsy do not respond to treatment with currently available drugs. The majority of these people have partial epilepsy. Vigabatrin is an antiepileptic drug licensed for ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/14651858.CD007302.pub2

データ提供：米国国立医学図書館（NLM）

Vigabatrin for Refractory Epilepsy: Hope on the Horizon

Epilepsy, a neurological condition affecting millions worldwide, can be challenging to treat. Approximately 30% of people with epilepsy don't respond to conventional antiepileptic medications. Vigabatrin, an antiepileptic drug, has shown promise in treating refractory epilepsy, particularly in cases of partial epilepsy. This research reviews the use of vigabatrin for refractory epilepsy, exploring its efficacy and potential side effects.

Vigabatrin's Role in Refractory Epilepsy

Vigabatrin, an antiepileptic drug, has been shown to be effective in treating refractory epilepsy, particularly in cases of partial epilepsy. While initial studies didn't identify major side effects, longer-term observational studies have linked its use to asymptomatic visual field constriction. This information provides valuable insight for clinicians to make informed decisions regarding the use of vigabatrin.

Balancing Benefits and Risks: A Desert Oasis of Knowledge

This research highlights the importance of balancing the potential benefits of vigabatrin with the risk of asymptomatic visual field constriction. This is like navigating a desert – the journey can be challenging, but the rewards are worth the risks. This study reminds us that even with the best medications, there is always a need for careful monitoring and weighing the benefits against potential side effects.

Dr.Camel's Conclusion

This review emphasizes the importance of personalized medicine in treating epilepsy. While vigabatrin offers hope for those with refractory epilepsy, careful monitoring for potential side effects is crucial. This is like navigating a desert – we need to be aware of both the beauty and the dangers to make the best decisions.

Date :
  1. Date Completed 2013-03-12
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

23440814

DOI: Digital Object Identifier

10.1002/14651858.CD007302.pub2

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.